Boston Partners Adds $121M in Labcorp Holdings Inc. ($LH)
Key Points
- Boston Partners changed its Labcorp Holdings Inc. ($LH) stake by 23.8% last quarter, boosting to 2,368,796 shares worth $628.37 million.
- Wall Street's consensus rating on $LH is Buy and an average price target of $310.12.
- $LH last traded around $265.27.
Boston Partners increased its position in Labcorp Holdings Inc. ($LH) by 23.8% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,368,796 shares of Labcorp Holdings Inc. after buying 455,101 shares during the quarter. Boston Partners's holdings in Labcorp Holdings Inc. were worth $628.37 million as of its most recent filing.
Labcorp Holdings Inc. ($LH) Stock
Labcorp Holdings Inc. Earnings
Labcorp Holdings Inc. Dividend
Analysts Set New Price Targets
About Labcorp Holdings Inc.
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
See Also
This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.